Product Description
Atara Biotherapeutics is developing ATA-2271 as a treatment for Mesothelioma & other solid tumors. (Sourced from: https://www.atarabio.com/pipeline/ata2271-ata3271/)
Mechanisms of Action: CAR-T
Novel Mechanism: No
Modality: Autologous CAR-T
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Allogene Therapeutics
Company Location: Western America
Company Founding Year: 2017
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Mesothelioma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/08/2022 |
News Article |
Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress |
|
08/08/2022 |
News Article |
Atara Biotherapeutics Announces Second Quarter 2022 Financial Results and Corporate Strategy Update |
|
05/19/2022 |
News Article |
Atara Biotherapeutics Provides Update on Strategic Collaboration with Bayer |
|
05/05/2022 |
News Article |
Atara Biotherapeutics Announces First Quarter 2022 Financial Results and Operational Progress |